|
1.
|
Schutte K, Bornschein J and Malfertheiner
P: Hepatocellular carcinoma-epidemiological trends and risk
factors. Dig Dis. 27:80–92. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
McGlynn KA, Tsao L, Hsing AW, Devesa SS
and Fraumeni JF Jr: International trends and patterns of primary
liver cancer. Int J Cancer. 94:290–296. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Harnois DM: Hepatitis C virus infection
and the rising incidence of hepatocellular carcinoma. Mayo Clin
Proc. 87:7–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Paul SB, Manjunatha YC and Acharya SK:
Palliative treatment in advanced hepatocellular carcinoma: has it
made any difference? Trop Gastroenterol. 30:125–134.
2009.PubMed/NCBI
|
|
5.
|
Ashkenazi A, Pai RC, Fong S, et al: Safety
and antitumor activity of recombinant soluble Apo2 ligand. J Clin
Invest. 104:155–162. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Mucha SR, Rizzani A, Gerbes AL, et al: JNK
inhibition sensitises hepatocellular carcinoma cells but not normal
hepatocytes to the TNF-related apoptosis-inducing ligand. Gut.
58:688–698. 2009. View Article : Google Scholar
|
|
7.
|
Voelkel-Johnson C: TRAIL-mediated
signaling in prostate, bladder and renal cancer. Nat Rev Urol.
8:417–427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hellwig CT and Rehm M: TRAIL signaling and
synergy mechanisms used in TRAIL-based combination therapies. Mol
Cancer Ther. 11:3–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Spagnuolo C, Russo M, Bilotto S, Tedesco
I, Laratta B and Russo GL: Dietary polyphenols in cancer
prevention: the example of the flavonoid quercetin in leukemia. Ann
NY Acad Sci. 1259:95–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Stagos D, Amoutzias GD, Matakos A, Spyrou
A, Tsatsakis AM and Kouretas D: Chemoprevention of liver cancer by
plant polyphenols. Food Chem Toxicol. 50:2155–2170. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Siddiqui IA, Malik A, Adhami VM, et al:
Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP
cells to TRAIL-mediated apoptosis and synergistically inhibits
biomarkers associated with angiogenesis and metastasis. Oncogene.
27:2055–2063. 2008. View Article : Google Scholar
|
|
12.
|
Jacquemin G, Shirley S and Micheau O:
Combining naturally occurring polyphenols with TNF-related
apoptosis-inducing ligand: a promising approach to kill resistant
cancer cells? Cell Mol Life Sci. 67:3115–3130. 2010. View Article : Google Scholar
|
|
13.
|
Luo X, Budihardjo I, Zou H, Slaughter C
and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c
release from mitochondria in response to activation of cell surface
death receptors. Cell. 94:481–490. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Wang S and El-Deiry WS: TRAIL and
apoptosis induction by TNF-family death receptors. Oncogene.
22:8628–8633. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Grunberger D, Banerjee R, Eisinger K, et
al: Preferential cytotoxicity on tumor cells by caffeic acid
phenethyl ester isolated from propolis. Cell Mol Life Sci.
44:230–232. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Ozturk G, Ginis Z, Akyol S, Erden G, Gurel
A and Akyol O: The anticancer mechanism of caffeic acid phenethyl
ester (CAPE): review of melanomas, lung and prostate cancers. Eur
Rev Med Pharmacol Sci. 16:2064–2068. 2012.PubMed/NCBI
|
|
17.
|
Khalil ML: Biological activity of bee
propolis in health and disease. Asian Pac J Cancer Prev. 7:22–31.
2006.PubMed/NCBI
|
|
18.
|
Szliszka E, Czuba ZP, Domino M, Mazur B,
Zydowicz G and Krol W: Ethanolic extract of propolis (EEP) enhances
the apoptosis-inducing potential of TRAIL in cancer cells.
Molecules. 14:738–754. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Szliszka E, Czuba ZP, Bronikowska J,
Mertas A, Paradysz A and Krol W: Ethanolic extract of propolis
augments TRAIL-induced apoptotic death in prostate cancer cells.
Evid Based Complement Alternat Med. 2011:5351722011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Szliszka E, Zydowicz G, Mizgala E and Krol
W: Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes
LNCaP prostate cancer cells to TRAIL-induced apoptosis. Int J
Oncol. 41:818–828. 2012.PubMed/NCBI
|
|
21.
|
Li X, Wang JN, Huang JM, et al: Chrysin
promotes tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL) induced apoptosis in human cancer cell lines.
Toxicol In Vitro. 25:630–635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Kim EY, Yu JS, Yang M and Kim AK:
Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through
ERK-dependent up-regulation of TRAIL receptor DR5. Mol Cells.
35:32–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Jin CY, Park C, Hwang HJ, et al:
Naringenin up-regulates the expression of death receptor 5 and
enhances TRAIL-induced apoptosis in human lung cancer A549 cells.
Mol Nutr Food Res. 55:300–309. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Nicholson DW: Caspase structure,
proteolytic substrates, and function during apoptotic cell death.
Cell Death Differ. 6:1028–1042. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Thorburn A: Death receptor-induced cell
killing. Cell Signal. 16:139–144. 2004. View Article : Google Scholar
|
|
26.
|
Kim HE, Du F, Fang M and Wang X: Formation
of apoptosome is initiated by cytochrome c-induced dATP hydrolysis
and subsequent nucleotide exchange on Apaf-1. Proc Natl Acad Sci
USA. 102:17545–17550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Zhang L and Fang B: Mechanisms of
resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther.
12:228–237. 2004. View Article : Google Scholar
|
|
28.
|
Kauntz H, Bousserouel S, Gosse F and Raul
F: The flavonolignan silibinin potentiates TRAIL-induced apoptosis
in human colon adenocarcinoma and in derived TRAIL-resistant
metastatic cells. Apoptosis. 17:797–809. 2012. View Article : Google Scholar
|
|
29.
|
Prasad S, Yadav VR, Kannappan R and
Aggarwal BB: Ursolic acid, a pentacyclin triterpene, potentiates
TRAIL-induced apoptosis through p53-independent up-regulation of
death receptors: evidence for the role of reactive oxygen species
and JNK. J Biol Chem. 286:5546–5557. 2011. View Article : Google Scholar
|
|
30.
|
Kelley RF, Totpal K, Lindstrom SH, et al:
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor
necrosis factor-related apoptosis-inducing ligand reveal a greater
contribution of death receptor (DR) 5 than DR4 to apoptosis
signaling. J Biol Chem. 280:2205–2212. 2005. View Article : Google Scholar
|
|
31.
|
Gupta SC, Reuter S, Phromnoi K, et al:
Nimbolide sensitizes human colon cancer cells to TRAIL through
reactive oxygen species- and ERK-dependent up-regulation of death
receptors, p53, and Bax. J Biol Chem. 286:1134–1146. 2011.
View Article : Google Scholar
|
|
32.
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Pimienta G and Pascual J: Canonical and
alternative MAPK signaling. Cell Cycle. 6:2628–2632. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Lepage C, Leger DY, Bertrand J, Martin F,
Beneytout JL and Liagre B: Diosgenin induces death receptor-5
through activation of p38 pathway and promotes TRAIL-induced
apoptosis in colon cancer cells. Cancer Lett. 301:193–202. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Lin FL, Hsu JL, Chou CH, Wu WJ, Chang CI
and Liu HJ: Activation of p38 MAPK by damnacanthal mediates
apoptosis in SKHep 1 cells through the DR5/TRAIL and
TNFR1/TNF-alpha and p53 pathways. Eur J Pharmacol. 650:120–129.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Lamy V, Bousserouel S, Gosse F, Minker C,
Lobstein A and Raul F: Lupulone triggers p38 MAPK-controlled
activation of p53 and of the TRAIL receptor apoptotic pathway in
human colon cancer-derived metastatic cells. Oncol Rep. 26:109–114.
2011.PubMed/NCBI
|
